FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

Dated December 1213, 2006

BIOMIRA INC.

(Translation of registrant’s name into English)

Edmonton Research Park

2011-94 Street, Edmonton, Alberta Canada T6N1H1

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x

(for past years through calendar year 1996)

Form 40-F x

(commencing in calendar year 1997)

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o

No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):

EXPLANATORY NOTE

On December 1213, 2006, Biomira Inc. ~~(i)~~ issued a press release announcing ~~an agreement~~ ~~with the U.S. Food and Drug Administration on~~ a ~~Special Protocol~~financing ~~Assessment for the planned Phase III clinical trial~~ of ~~Stimuvax(R)~~approximately ~~for~~$13 ~~the treatment~~million ~~of non-small cell lung cancer and~~ (iiU.S.) ~~filed with~~pursuant ~~the~~to ~~System~~its ~~for~~current ~~Electronic~~shelf ~~Document Analysis and Retrieval in Canada~~registration ~~a Material~~ statement ~~Change~~on ~~Report~~Form ~~related~~F-10 to(File ~~the~~No. ~~announcement~~333-137342). A copy of the press release ~~is attached to this report as Exhibit 1 and a~~ ~~copy of the Material Change Report~~ is attached to this report as Exhibit 21.

EXHIBIT INDEX

Exhibit Number		Description of Document
1		Press Release dated December 1213, 2006
2		Material Change Report dated December 12, 2006

Forward-Looking Statements

In order to provide our investors with an understanding of our current results and future prospects, the referenced press release may contain statements that are forward looking. These forward-looking statements represent Biomira’s intentions, plans, expectations and beliefs and are based on our experience and our assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties related to our business and the general economic environment, many beyond our control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements, including those predicting adequacy of financing and reserves on hand; currency exchange rate fluctuations; changes in general accounting policies; and general economic factors. Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in Canada and the United States, including the risk factors described in our 2005 Annual Report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOMIRA INC.
	(Registrant)
Date: December 12, 2006	By:	/s/ Edward A. Taylor
Date: December 13, 2006	By:	/s/ Edward A. Taylor
		Edward A. Taylor Vice President, Finance & Administration and Chief Financial Officer

Filing Compare · BIOMIRA INC